Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezoli...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2021-05, Vol.148 (10), p.2557-2570
Main Authors: Daniel, Davey, Kuchava, Vladimer, Bondarenko, Igor, Ivashchuk, Oleksandr, Reddy, Sreekanth, Jaal, Jana, Kudaba, Iveta, Hart, Lowell, Matitashvili, Amiran, Pritchett, Yili, Morris, Shannon R., Sorrentino, Jessica A., Antal, Joyce M., Goldschmidt, Jerome
Format: Article
Language:English
Subjects:
Adverse events
Cancer
Cancer Therapy and Prevention
Carboplatin
Chemotherapy
Cyclin-dependent kinase 4
Double-blind studies
Erythrocytes
Etoposide
Hematopoietic stem cells
Immune system
Immunotherapy
Intravenous administration
Leukocytes (neutrophilic)
Lung cancer
Medical research
Monoclonal antibodies
myelopreservation
Myelosuppression
Neutropenia
Placebos
Progenitor cells
Quality of life
small cell lung cancer (SCLC)
Small cell lung carcinoma
Statistical analysis
Stem cells
Targeted cancer therapy
Toxicity
trilaciclib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to preserve haematopoietic stem and progenitor cells and immune system function from chemotherapy‐induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezolizumab (E/P/A) were evaluated in a randomised, double‐blind, placebo‐controlled Phase II study in patients with newly diagnosed extensive‐stage small cell lung cancer (ES‐SCLC) (NCT03041311). The primary endpoints were duration of severe neutropenia (SN; defined as absolute neutrophil count
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.33453